Dr Muhammed Majeed, founder and Chairman of Sami-Sabinsa Group, has recently published his fourth book in a series on derivatives of Boswellia serrata.
Boswellin- Anti-Inflammatory Adaptogen from Nature was edited by Dr Majeed and Dr N. Kalyanam, and written by other senior scientists of Sami-Sabinsa Group. This book focuses on the reportedly long-ignored polysaccharide component of Boswellia gum.
Boswellic acids are obtained from the gum resin of Boswellia serrata tree, a large, branching, deciduous tree which grows abundantly in the dry, hilly parts of India. It is known as Dhup, Indian frankincense, or Indian olibanum. The gum resin exudate of Boswellia serrata, known in the vernacular as ‘Salai guggal’, is used in the Ayurvedic system of medicine for the management of rheumatism, respiratory diseases, and liver disorders. The primary use of Boswellia serrata in contemporary medicine is as an anti-arthritic and anti-inflammatory pharmacological agent.
The Boswellin range of extracts was introduced 1990s. Sami-Sabinsa recognised the anti-inflammatory benefits of Boswellic acids, the active components of Boswellia, by their reported LOX inhibition, it says. Boswellin PS is composed of both Boswellic acids and polysaccharide of the gum (Polysal).
“With many botanicals, there is so much more to study than the primarily-known active constituents,” said Dr Majeed. “In studying Boswellia, we’ve made some intriguing discoveries about the immunomodulatory polysaccharides of Boswellia gum, and are eager to share those more widely.”
